Viatris posts Q4 revenue beat on strong performance in Greater China and Emerging Markets

Viatris

26/02/2026 12:09

Overview

Healthcare firm's Q4 revenue rose 5%, beating analyst expectations

Adjusted EPS for Q4 beat analyst expectations, rising 6% yr/yr

Company returned over $1 bln to shareholders in 2025

Outlook

Viatris expects 2026 revenue between $14.45 bln and $14.95 bln

Company anticipates $450 mln to $550 mln in new product revenues for 2026

Viatris plans $650 mln in cost savings over next three years

Result Drivers

BRANDS PERFORMANCE - Strong brands performance in Greater China and Emerging Markets drove Q4 revenue growth

NEW PRODUCT LAUNCHES - New product launches contributed $78 mln to Q4 revenue, offsetting generics sales challenges

STRATEGIC REVIEW - Enterprise-wide strategic review aims for $650 mln in cost savings to enhance growth

Company press release: ID:nPn5bkS9pa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$3.70 bln
$3.53 bln (6 Analysts)
Q4 Adjusted EPS
Beat
$0.57
$0.53 (7 Analysts)
Q4 EPS
-$0.30


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Viatris Inc is $13.56, about 15.7% below its February 25 closing price of $16.08

The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 4 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)